Sarfez Pharmaceuticals has developed formulation technologies such as matrix-based extended-release (MEXFOR), rapid-action orally-disintegrating technology (ROTEC), and self-emulsifying drug delivery system (SEEDS). The company's lead candidate is an extended-release diuretic currently in clinical trials. With 8 programs in its R&D pipeline, Sarfez is developing protein inhibitors and novel loop diuretics for various conditions including hypertension, cardiac fibrosis, pancreatitis, diabetic nephropathy, nephrotic syndrome, and congestive heart failure. The company has formed alliances with Recipharm, Hetero, and Syngene. Sarfez Pharmaceuticals is led by a team of experienced professionals in the scientific and drug development community, including academic leaders, renowned physicians, and scientists specializing in nephrology and hypertension.